Cargando…

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.

Detalles Bibliográficos
Autores principales:	Mangasarova, Ya.K., Moiseeva, T.N., Al-Radi, L.S., Margolin, O.V., Gorenkova, L.G., Nesterova, E.S., Bagova, M.O., Fastova, E.A., Abdurashidova, R.R., Sarakaeva, Z.T., Dorokhina, Elena, Kravchenko, S.K., Magomedova, A.U., Zvonkov, E.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621492/ http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41

Ejemplares similares

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
por: Dorokhina, Elena, et al.
Publicado: (2022)

P019: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
por: Dorokhina, Elena, et al.
Publicado: (2022)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

P1207: MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR
por: Magomedova, A., et al.
Publicado: (2022)

Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy
por: Mo, Jiajie, et al.
Publicado: (2023)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis
por: Albakova, Zarema, et al.
Publicado: (2022)

Corrigendum: HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis
por: Albakova, Zarema, et al.
Publicado: (2023)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
por: Shupletsova, Irirna, et al.
Publicado: (2022)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

Managing Substance Use Disorder through a Walking/Running Training Program
por: Dai, Chia-Liang, et al.
Publicado: (2020)

PB2344: STR-LOCI ALLELE IMBALANCE AT 9P24.1 AND PD-L1 EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
por: Abdurashidova, Runiza, et al.
Publicado: (2023)

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
por: Risinskaya, Natalya, et al.
Publicado: (2022)

Specific Aspects of Eye Movement Reactions as Markers of Cognitive Control Disorders in Patients with Obsessive-Compulsive Disorder (Review)
por: Khayrullina, G.M., et al.
Publicado: (2022)

Work engagement and workers’ health, is there any connection in the social work in ukraine?
por: Dorokhina, A., et al.
Publicado: (2021)

Associations of Biochemical Changes and Maternal Traits with Mutation 1843 (C>T) in the RYR1 Gene as a Common Cause for Porcine Stress Syndrome
por: Popovski, ZT, et al.
Publicado: (2016)

Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke
por: Kurakina, А.S., et al.
Publicado: (2021)

COVID-19 in Patients with Diabetes: Clinical Course, Metabolic Status, Inflammation, and Coagulation Disorder
por: Belikina, D.V., et al.
Publicado: (2020)

The HSP Immune Network in Cancer
por: Albakova, Zarema, et al.
Publicado: (2021)

Comparative Analysis of the Hemostasiological Profile in Sheep and Patients with Cardiovascular Pathology as the Basis for Predicting Thrombotic Risks During Preclinical Tests of Vascular Prostheses
por: Gruzdeva, O.V., et al.
Publicado: (2021)

Integral and Local Methods for the Evaluation of the Hemostasiological Profile in Sheep at Various Stages of Implantation of a Biodegradable Vascular Graft
por: Gruzdeva, O.V., et al.
Publicado: (2022)

Jeux de langage et d'écriture : Littératurbulences: 7-14 ans /
por: Rivais, Yak, 1939-
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_ej3eijoi4a24hiv0isbt8dc88c